GlobeNewswire Inc.··Argenx Seargenx Expands VYVGART Leadership with Positive Phase 3 Data Across MG and CIDP
argenx presents Phase 3 data supporting VYVGART expansion across ocular MG, seronegative MG, and treatment-naïve CIDP, with 87.5% early benefit rates.
ARGXFDA approvalPhase 3 trials